Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Clin Rev Allergy Immunol. 2010 Feb;38(1):39-53. doi: 10.1007/s12016-009-8131-4.
Of the six cytokine therapies approved by the US Food and Drug Administration, five of them have been used in patients with primary immunodeficiency (PID). In some applications, clear benefits have been demonstrated, while in others, effects have been more marginal. The most compelling current applications of cytokine therapy in PID are those of granulocyte colony stimulating factor in severe congenital neutropenia and interferon gamma in chronic granulomatous disease. Despite encouraging results with interleukin-2 in common variable immunodeficiency and select other indications, its use in PID is not widespread.
在美国食品和药物管理局批准的六种细胞因子疗法中，有五种已用于原发性免疫缺陷（PID）患者。在某些应用中，已证明有明显的益处，而在其他情况下，效果则更为有限。细胞因子疗法在 PID 中的最引人注目的当前应用是粒细胞集落刺激因子治疗严重先天性中性粒细胞减少症和干扰素γ治疗慢性肉芽肿病。尽管白细胞介素-2在常见可变免疫缺陷和其他一些适应症中取得了令人鼓舞的结果，但在 PID 中的应用并不广泛。
